Halozyme Therapeutics, Inc. (HALO)
After hours:
| Previous Close | 39.82 |
| Open | 40.67 |
| Bid | 39.83 x 100 |
| Ask | 46.06 x 100 |
| Day's Range | 39.79 - 40.74 |
| 52 Week Range | 29.85 - 45.00 |
| Volume | |
| Avg. Volume | 998,148 |
| Market Cap | 5.071B |
| Beta (5Y Monthly) | 1.25 |
| PE Ratio (TTM) | 19.00 |
| EPS (TTM) | 2.10 |
| Earnings Date | May 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 51.11 |
Insider MonkeyHow Novo-Catalent Deal Affects Halozyme (HALO)?
Laughing Water Capital, an investment management company, released its first-quarter 2024 investor letter. A copy of the same can be downloaded here. In the first quarter, investment in the fund returned 8.4% after all fees and expenses compared to 10.6% and 5.2% returns for the SP500TR and R2000 during the quarter, respectively. In addition, you […]
ZacksHalozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PR NewswireMahesh Krishnan Elected to Halozyme's Board of Directors
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services.
